孙沃泽提尼布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
桑沃泽提尼布是一种新的非小细胞肺癌 (NSCLC) 的口服治疗方法,具有特定的EGFR外基因组20插入突变. 它在第二阶段试验中获得了基于有希望的响应率的条件批准.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 桑沃泽提尼布是一种口服的,不可逆转的表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI).
- 它针对特定的EGFR突变,包括外子20插入 (exon20ins),对野生类型的EGFR活动有限.
- 迪扎尔制药公司开发了sunvozertinib用于非小细胞肺癌 (NSCLC) 治疗.
研究的目的:
- 总结一下sunvozertinib的发展里程碑.
- 为了突出其首次批准的转移性NSCLC与EGFR exon20ins突变.
主要方法:
- 基于单臂第二阶段试验的条件批准.
- 评估整体反应率和反应持续时间.
- 目前正在进行确认性第三阶段随机试验,以获得全面批准.
主要成果:
- 桑沃泽提尼布在2023年8月获得了第一个有条件批准.
- 已被批准用于局部晚期或转移性NSCLC的成年患者,具有EGFR exon20ins突变.
- 适用于进展或不耐基化疗的患者.
结论:
- 对于EGFR exon20ins.的NSCLC患者来说,sunvozertinib代表了显著的进步.
- 有条件的批准意味着有希望的疗效,等待第三阶段试验结果.
- 全球范围内正在进行进一步的临床研究.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
相关概念视频
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment Resistant Cancers
Drug Regulation
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
